SavedAdd your journal

Journals / Çocuk Dergisi / 2026 / Cilt: 25 Sayı: 3

Successful Treatment of MuSK Antibody–Positive Myasthenia Gravis with Rituximab

Arife Derda Yücel Şen(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF NEUROLOGY)0000-0002-2656-5611
Ahmet Baysal(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF NEUROLOGY)0000-0002-5909-1918
Özlem Uğur(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF NEUROLOGY)0000-0001-9257-085X
Kürşat Bora Çarman(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF NEUROLOGY)0000-0002-4629-1873
Coşkun Yarar(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF NEUROLOGY)0000-0001-7462-4578
Pages
172–175
Publication Date
2025-10-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies.
📊
Key Findings & Data:Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults.
💡
Conclusion & Impact:We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.
🔬Design:Olgu Sunumu
📍Scope:Comprehensive Sample
⚙️Variables:Child · myasthenia gravis · MUSK

Abstract

Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies. Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults. We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.

🔖

Cite This Article

Şen, A. D. Y., Baysal, A., Uğur, Ö., Çarman, K. B., Yarar, C. (2025). Successful Treatment of MuSK Antibody–Positive Myasthenia Gravis with Rituximab. Çocuk Dergisi, Cilt: 25 Sayı: 3, 172–175. https://doi.org/10.26650/jchild.2025.1704940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gilhus NE, Verschuuren JJ. MYasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023-36. google scholar
  2. Deymeer F. MYasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta MYol. 2020;39:345-52. google scholar
  3. Tannemaat MR, Huijbers MG, Verschuuren JJGM. MYasthenia gravis-Pathophysiology, diagnosis, and treatment. Handb Clin Neurol. 2024;200:283-305. google scholar
  4. Vesperinas-Castro A, Cortes-Vicente E. Rituximab treatment in mYasthenia gravis. Front Neurol. 2023;14:1275533. google scholar
  5. Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-Associated MYasthenia Gravis: Clinical Features and Management. Front Neurol. 2020;11:660. google scholar
  6. Evoli A, Alboini PE, Damato V, et al. MYasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412:82-9. google scholar
  7. Sanders DB, El-Salem K, MasseY JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. NeurologY. 2003;60:1978-80. google scholar
  8. Huda S, Waters P, Woodhall M, et al. IgG-specific cell-based assaY detects potentiallY pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm. 2017;4:357. google scholar
  9. Anlar B, Yilmaz V, Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile mYasthenia. Pediatr Neurol. 2009;40:455-6. google scholar
  10. Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK mYasthenia gravis: Multicenter blinded prospective review. NeurologY. 2017;89:1069-77. google scholar
  11. Topakian R, Zimprich F, Iglseder S, et al. High efficacY of rituximab for mYasthenia gravis: a comprehensive nationwide studY in Austria. J Neurol. 2019;266:699-06. google scholar
  12. O'Connell K, Ramdas S, Palace J. Management of Juvenile MYasthenia Gravis. Front Neurol. 2020;11:743. google scholar